S&P 500 Hits New Record Highs as the Dow Gains

We're back to breaching record highs on the markets this week as the Dow Jones Industrial Average (DJINDICES: ^DJI  ) continues its march upward. As of 2:30 p.m. EST, the Dow has gained 93 points -- down from triple-digits earlier in trading -- and sits only about 200 points off the all-time high set last year. Nearly every blue-chip stock on the Dow is gaining ground today, with Big Pharma's Merck (NYSE: MRK  ) among the best by pulling down a 1% jump. Meanwhile, the S&P 500 (SNPINDEX: ^GSPC  ) hit a new intraday high today by gaining around 0.5%. Let's catch up on what you need to know.

Shakiness in the U.S. economy?

The economy kicked things off with disappointing but expected news today. U.S. GDP grew at an annual rate of just 2.4% in the fourth quarter, below the 3.2% economists initially had predicted. Consumer spending gained less than projected, picking up just 2.6% for the quarter. With the winter's harsh weather negatively impacting the first quarter, economists are questioning if the American economy's progress will slow in the early going of 2014.

Still, the gains posted aren't anywhere near worrying territory yet: Exports gained more than 9% during the fourth quarter, and much of the losses for the economy came from a 5% reduction in government spending. For American businesses, the U.S. economy still looks in great shape heading forward – even if it's not advancing as fast as everyone hopes.

The report hasn't hurt the Dow at all today, and Merck's stock hasn't shown the faintest signs of weakness during the day's run. Merck hasn't reported much in the way of news, but investors have rallied behind the company's increasing momentum as of late. The stock has picked up more than 14% year to date, overcoming the Street's shakiness early in January. While Merck's performance hasn't turned heads yet -- the company's most recent earnings report fell below analyst bottom-line expectations as the company's ballyhooed diabetes drugs Januvia and Janumet struggle to find more than modest growth -- Wall Street has pushed hard behind the company's up-and-coming drugs that could promise billions of dollars in future annual revenue.

Nothing else in Merck's pipeline approaches the promise of MK-3475, a cancer therapy under consideration by the FDA for the treatment of melanoma. Analysts have upgraded annual sales projections of the drug in 2014, with many now expecting between $3 billion and $4 billion in annual revenue from MK-3475 down the road, assuming it can pick up approval for more indications in the near future. However, Merck's all-oral hepatitis C therapy, while not among the first drugs hitting the market, also has impressed. Merck's current hepatitis C med, Victrelis, has lost steam lately. While the company has a long way to go to catch up to the leaders in this potentially $20 billion market -- Gilead Sciences' (NASDAQ: GILD  ) Sovaldi gained approval last December and may one day hit $7 billion or more in peak annual sales -- Merck's still pushing its own all-oral hep C therapy hard.

Have you made the most of the market's rise?
Millions of Americans have waited on the sidelines since the market meltdown in 2008 and 2009, too scared to invest and put their money at further risk. Yet those who've stayed out of the market have missed out on huge gains and put their financial futures in jeopardy. In our brand-new special report, "Your Essential Guide to Start Investing Today," The Motley Fool's personal finance experts show you why investing is so important and what you need to do to get started. Click here to get your copy today -- it's absolutely free.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2859610, ~/Articles/ArticleHandler.aspx, 8/31/2015 10:05:58 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Dan Carroll

Dan began writing for the Motley Fool in 2012. He is a health care specialist who also follows the defense industry along with tracking the broader U.S. and international markets.

Today's Market

updated 49 minutes ago Sponsored by:
DOW 16,528.03 -114.98 -0.69%
S&P 500 1,972.18 -16.69 -0.84%
NASD 4,776.51 -51.82 -1.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/31/2015 4:57 PM
^DJI $16528.03 Down -114.98 -0.69%
^GSPC $1972.18 Down -16.69 -0.84%
S&P 500 INDEX CAPS Rating: No stars
GILD $105.07 Down -2.71 -2.51%
Gilead Sciences CAPS Rating: *****
MRK $53.85 Down -1.52 -2.75%
Merck & Co., Inc. CAPS Rating: ****